We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Circulating DNA Distinguishes Benign from Malignant Prostate Disease

By LabMedica International staff writers
Posted on 16 Nov 2010
Free circulating DNA (fcDNA) that has been released into the blood after tumor cell death can be measured as a biomarker for cancer. More...


In patients with prostate cancer (CaP), increased fcDNA is found in men with metastatic CaP as compared to controls, but not in men with localized CaP. Serum fcDNA can be measured by real-time polymerase chain reaction for the glutathione S-transferase, pi gene (GSTP1). GSTP1 variant proteins are thought to function in xenobiotic metabolism and play a role in susceptibility to cancer, and other diseases

Scientists at the University of Miami (Miami, FL, USA) prospectively evaluated fcDNA in 252 men who have undergone CaP screening and prostate biopsy to correlate levels in relation to the demographic and clinicopathologic features. Among the patients in the study, at prostate biopsy, 89 had CaP, 59 had prostatitis, and 104 had benign prostatic hyperplasia (BPH). The median fcDNA levels for CaP, BPH and prostatitis were 149 ng/mL, 96.9 ng/mL, and 81.8 ng/mL, respectively. There was no statistical difference between prostatitis and BPH regarding fcDNA levels, but the difference was statistically significant for CaP versus benign etiologies.

When stratified by total prostate specific antigen (PSA) levels, the results showed that for patients with a PSA of less than 10 ng/mL, the difference remained significant. However, there was no significant difference in fcDNA levels for CaP versus benign causes in patients with PSA greater than 10 ng/mL. An interaction between fcDNA and PSA yielded a high negative predictive value of 93.1% and increased specificity of 33.1% compared with negative predictive value of 73.3% and specificity of 6.7% in the model excluding fcDNA. Prostate cancer was diagnosed in 35.3% of the patients whose mean age was 66 years, compared with 63 years in both prostatitis patients and in BPH patients. The CaP group had a significantly higher percentage of African-American patients (48%) compared with prostatitis (17%).

The authors stated that the main inference from the study was that by adding fcDNA to prostate cancer screening the number of unnecessary prostate biopsies can be reduced. The study was published in August 2010, in the journal Cancer Epidemiology and Biomarkers Prevention.

Related Links:

University of Miami




New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.